Skip to content
Screener

Monopar Therapeutics MNPR Q1 2026 Annual earnings

Reported May 14, 2026 · Before market open

Revenue-
EPS-$0.46Beat by $0.60
EPS estimate-$1.06

Next report

Nov 6, 2026 (in 3 months)
EPS estimate-$0.77

Financials

Q1 2026

Income statement

See full
Revenue-—
Operating income-$5.2M-62.2%
Net income-$3.9M-48.3%

Balance sheet

See full
Cash & equivalents$52.5M+32.3%
Total debt$230.4K+2,692%
Total equity$135.4M+153%
Total assets$138.0M+150%

Cash flow

See full
Operating cash flow-$3.5M+38.7%

Valuation & ratios

Valuation

as of 08/11/26
See full
Market cap$798.6M+307%
Enterprise value$746.28M+378%

Returns & leverage

See full
Return on equity-15.9%-6.6pp
Debt / equity0×0.0×
Current ratio56×—

FAQ

When did Monopar Therapeutics report Q1 2026 earnings?
Monopar Therapeutics (MNPR) reported Q1 2026 earnings on May 14, 2026 before market open.
What were Monopar Therapeutics's Q1 2026 revenue and EPS?
Monopar Therapeutics reported revenue of - and eps of $-0.46 for Q1 2026.
Did Monopar Therapeutics beat estimates in Q1 2026?
EPS beat the consensus estimate of $-1.06 by $0.60.
How did Monopar Therapeutics's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, eps declined 21.1% from $-0.38.
Where can I find Monopar Therapeutics's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001437749-26-016981) and the 10-K/A periodic report (0001437749-26-010841) directly on SEC EDGAR. The filing index links above go to sec.gov.